Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

ROG - Roche Holding AG - Stock Price & Dividends

Exchange: SIX Swiss Exchange • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012032048

Pharmaceuticals, Diagnostics, Cancer, Diabetes, Covid-19

Roch Holding AG is a multinational healthcare company that operates in the pharmaceuticals and diagnostics sectors, serving a global market that spans Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

The company's pharmaceutical division focuses on developing and marketing treatments for a wide range of therapeutic areas, including anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune diseases, neurological disorders, ophthalmology, respiratory disorders, and transplantation. Its product portfolio is designed to address various stages of disease progression, from prevention and diagnosis to treatment and management.

In addition to its established products, Roche Holding AG is also committed to research and development, with a focus on creating innovative treatments for various therapeutic areas. This includes investing in cutting-edge technologies, such as gene therapy and immunotherapy, to address unmet medical needs.

The diagnostics division of Roche Holding AG offers a comprehensive range of in vitro tests for the diagnosis of various diseases, including cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other conditions. These tests are designed to provide accurate and reliable results, enabling healthcare professionals to make informed treatment decisions.

Furthermore, the company provides diagnostic instruments and digital health solutions to support healthcare professionals in their daily work. These solutions include data analytics and interpretation tools, which help to streamline workflows and improve patient outcomes.

Roch Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. With a rich history spanning over 125 years, the company has established itself as a leader in the global healthcare industry, committed to improving the lives of patients and families around the world.

For more information about Roche Holding AG, please visit their website at https://www.roche.com.

Drawdown (Underwater) Chart

Overall Trend and Yearly Seasonality

ROG Stock Overview

Market Cap in USD	251,422m
Sector	Healthcare
Industry	Drug Manufacturers - General
GiC SubIndustry	Pharmaceuticals
TER	0.00%
IPO / Inception

ROG Stock Ratings

Growth 5y	1.05
Fundamental	66.5
Dividend	62.3
Rel. Performance vs Sector	1.02
Analysts	-
Fair Price Momentum	268.38 CHF
Fair Price DCF	646.13 CHF

ROG Dividends

Dividend Yield 12m	3.36%
Yield on Cost 5y	4.22%
Dividends CAGR 5y	1.77%
Payout Consistency	100.0%

ROG Growth Ratios

Growth 12m	10.57%
Growth Correlation 12m	-16%
Growth Correlation 3m	79%
CAGR 5y	4.68%
CAGR/Mean DD 5y	0.28
Sharpe Ratio 12m	0.27
Alpha vs SP500 12m	-0.21
Beta vs SP500 5y weekly	0.35
ValueRay RSI	96.37
Volatility GJR Garch 1y	17.03%
Price / SMA 50	15.01%
Price / SMA 200	22.11%
Current Volume	1732.2k
Average Volume 20d	1271.4k

External Links for ROG Stock

Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle

What is the price of ROG stocks?
As of July 27, 2024, the stock is trading at CHF 286.00 with a total of 1,732,204 shares traded.
Over the past week, the price has changed by +2.77%, over one month by +14.58%, over three months by +29.41% and over the past year by +10.08%.

What are the forecast for ROG stock price target?
According to ValueRays Forecast Model, ROG Roche Holding AG will be worth about 292.6 in July 2025. The stock is currently trading at 286.00. This means that the stock has a potential upside of +2.32%.

Issuer	Forecast	Upside
Wallstreet Target Price	269.7	-5.69
Analysts Target Price	-	-
ValueRay Target Price	292.6	2.32

A Deep Dive into Roche Holding AG: From Origins to Global Healthcare Dominance

History of Roche Holding AG

Founded in 1896 by Fritz Hoffmann-La Roche in Basel, Switzerland, Roche Holding AG has grown from a small drug laboratory into a global powerhouse in healthcare. The company began with an emphasis on producing reliable pharmaceutical products and soon became known for innovations, such as the synthesis of Vitamin C in the 1930s. Over decades, Roche has consistently invested in research and development, leading to breakthroughs in various medical fields.

Core Business

Roche’s core business focuses on pharmaceuticals and diagnostics. Its pharmaceutical division is renowned for developing innovative treatments, especially in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Meanwhile, the diagnostics division offers a wide range of testing solutions, playing a crucial role in personalized healthcare by enabling faster and more accurate diagnosis and treatment.

Side Business and Ventures

Beyond its primary operations, Roche has diversified its business by investing in genomic research and data-driven medical insights through subsidiaries such as Foundation Medicine and Flatiron Health. These ventures underscore Roche’s commitment to advancing precision medicine, leveraging big data and analytics to improve patient care.

Current Market Status

As of the latest reports, Roche Holding AG continues to be a leading player in the global healthcare market. Its commitment to innovation and significant R&D investment have ensured a robust product pipeline and sustained growth. Despite challenges such as patent expiries and market competition, Roche’s strategic acquisitions and focus on emerging fields like personalized healthcare and digital health solutions position it well for future success.